Global Hospital Acquired Infections Therapeutic Market (2021 to 2028) – Featuring Pfizer, Bayer and GlaxoSmithKline Among Others – ResearchAndMarkets.com

Global Hospital Acquired Infections Therapeutic Market (2021 to 2028) – Featuring Pfizer, Bayer and GlaxoSmithKline Among Others – ResearchAndMarkets.com




Global Hospital Acquired Infections Therapeutic Market (2021 to 2028) – Featuring Pfizer, Bayer and GlaxoSmithKline Among Others – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Hospital Acquired Infections Therapeutic Market Share, Size, Trends, Industry Analysis Report, By Drug Class; By Infection Type; By Regions; Segment Forecast, 2021 – 2028” report has been added to ResearchAndMarkets.com’s offering.

The global hospital acquired infections therapeutic market size is expected to reach USD 12.52 billion by 2028 according to a new study. The report gives a detailed insight into current market dynamics and provides analysis on future market growth.

Rising tolerance towards antibiotics in lethal pathogens also induced the market demand for novel therapeutics for treating hospital acquired infections. The majority of players in the market for hospital acquired infections therapeutic are continuously involved in research & development activities to develop new drugs to gain a competitive advantage.

In this direction, in June 2019, Food & Drug Administration (FDA) approved Merck’s Zerbaxa (ceftolozane and tazobactam) drug for the treatment of ventilator-associated infections in patients aged 18 years and older. This is expected to drive the market for hospital acquired infections therapeutic.

Over the past few decades, chronic diseases such as diabetes, heart-related ailments, and arthritis are rising at an alarming speed. As per the data published by International Agency for Research on Cancer (IARC), in 2018, reported around 18.1 million new cancer cases.

This has resulted in a rise in healthcare admissions and an increased possibility of getting an hospital acquired infection. Moreover, as per the data of the New York State Department of Health in November 2019, more than 40% of the adults in the state suffer from some form of chronic disorder, accounting for around 23% of all the hospitalizations.

Asia Pacific is expected to register a lucrative market growth rate over the hospital acquired infection therapeutic study period. This market growth for hospital acquired infection therapeutic is attributed to the rising prevalence of chronic diseases in developing nations with high disposable income, which had led to an increase in hospital admissions.

The publisher segmented the hospital acquired infections therapeutic market report on the basis of drug class, infection type, and region:

Hospital Acquired Infections Therapeutic, Drug Class Outlook

  • Antibacterial Drugs
  • Cell Wall Synthesis Inhibitors
  • Protein Synthesis Inhibitors
  • Others
  • Antiviral Drugs
  • Antifungal Drugs

Hospital Acquired Infections Therapeutic, Infection Type Outlook

  • Urinary Tract Infections
  • Ventilator-associated Pneumonia
  • Surgical Site Infections
  • Bloodstream Infections
  • Other Hospital Infections

Hospital Acquired Infections Therapeutic, by Regional Outlook

  • North America
  • US
  • Canada
  • Europe
  • France
  • Germany
  • UK
  • Italy
  • Spain
  • Netherlands
  • Austria
  • Asia Pacific
  • China
  • India
  • Japan
  • Malaysia
  • South Korea
  • Indonesia
  • Central & South America
  • Mexico
  • Brazil
  • Argentina
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa

Key Topics Covered:

1. Introduction

2. Executive Summary

3. Research Methodology

4. Hospital Acquired Infections Therapeutic Market Insights

5. Hospital Acquired Infections Therapeutic Market Assessment by Drug Class

5.1. Key Findings

5.2. Introduction

5.3. Antibacterial Drugs

5.4. Antiviral Drugs

5.5. Antifungal Drugs

6. Global Hospital Acquired Infections Therapeutic Market, by Infection Type

6.1. Key Findings

6.2. Introduction

6.3. Urinary Tract Infections

6.4. Ventilator-associated Pneumonia

6.5. Surgical Site Infections

6.6. Bloodstream Infections

6.7. Other Hospital Infections

7. Hospital Acquired Infections Therapeutic Market Assessment by Geography

7.1. Key findings

7.2. Introduction

7.3. Hospital Acquired Infections Therapeutic Market – North America

7.4. Hospital Acquired Infections Therapeutic Market – Europe

7.5. Hospital Acquired Infections Therapeutic Market – Asia-Pacific

7.6. Hospital Acquired Infections Therapeutic Market – Middle East & Africa

7.7. Hospital Acquired Infections Therapeutic Market – Latin America

8. Competitive Landscape

8.1. Expansion and Acquisition Analysis

8.2. Partnerships/Collaborations/Agreements/Exhibitions

9. Company Profiles

9.1. Merck & Co., Inc.

9.2. Pfizer Inc.

9.3. Bayer AG

9.4. GlaxoSmithKline Plc.

9.5. Daiichi Sankyo Company, Limited

9.6. AbbVie Inc.

9.7. Abbott Laboratories

9.8. Allergan Plc.

9.9. F. Hoffmann-La Roche Ltd

9.10. Basilea Pharmaceutica AG

For more information about this report visit https://www.researchandmarkets.com/r/bdvehi

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900